EPO and stage 5 chronic kidney disease: Therefore, this study aimed to determine whether a biosimilar DA-α has similar efficacy and safety as that of EPO when given at a reduced dose frequency for the treatment of renal anemia in Indian patients with end-stage renal disease (ESRD) undergoing dialysis.